TLR5 and neoplasm: In breast cancer, the TLR5 agonist activates the intrinsic signaling pathway leading to the upregulation of IFN-γ and IL-4 population and lowering of the proportion of regulatory T cells that results in cell proliferation and suppressing the tumor growth (343).